An observational study in NAFLD, Heart Failure and Valvular Disease, sponsored by Dr. Andreas Kammerlander. Status unknown at 1 site in Austria. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2020-01-07.
Sponsored by Dr. Andreas Kammerlander · Observational
On clinically indicated Cardiovascular Magnetic Resonance studies, native T1-times and extracellular volume of the liver will be assessed and findings correlated with established risk calculators for non-alcoholic fatty liver disease.
2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.
This study's planned enrollment of 800 is above the median of 167 across 681 observational studies indexed under Liver Diseases.
Browse Liver Diseases studies →This is the only study on the registry with Dr. Andreas Kammerlander as lead sponsor.
Counted across the registry records on this site, refreshed daily.
All-comer cohort referred for Cardiovascular Magnetic Resonance Imaging
Exclusion Criteria:
On clinically indicated Cardiovascular Magnetic Resonance Imaging Studies, native T1-times and extracellular volume will be determined
Correlation NAFLD and liver T1mapping
Correlation NAFLD risk score and liver T1-mapping (native and ECV9
Time frame: cross-sectional within one year
Plan to share: No
This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.